Tagaya Y, Matsuoka M, Gallo R.

40 years of the human T-cell leukemia virus: past, present, and future.

F1000Res. 2019 Feb 28;8:F1000 Faculty Rev-228. doi: 10.12688/f1000research.17479.1. PMID: 30854194; PMCID: PMC6396841.

https://pubmed.ncbi.nlm.nih.gov/30854194/

Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T.

New Target investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

Int J Hematol .2019 Apr;109(4):426-439.  doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb14.PMID: 30762219

https://pubmed.ncbi.nlm.nih.gov/30762219/

Ito R, Inamoto Y, Inoue Y, Ito A, Tanaka T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Yamashita T, Fukuda T.

Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients.

Biol Blood Marrow Transplant. 2019 Feb;25(2):293-300. doi: 10.1016/j.bbmt.2018.09.014. Epub 2018 Sep 19. PMID: 30244104.

https://pubmed.ncbi.nlm.nih.gov/30244104/

Inoue Y, Endo S, Matsuno N, Kikukawa Y, Shichijo T, Koga K, Takaki A, Iwanaga K, Nishimura N, Fuji S, Fukuda T, Nosaka K, Matsuoka M.

Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.

Bone Marrow Transplant. 2019 Feb;54(2):338-342. doi: 10.1038/s41409-018-0291-5. Epub 2018 Aug 16. PMID: 30116017.

https://pubmed.ncbi.nlm.nih.gov/30116017/

Ishida T, Jo T, Takemoto S, Suzushima H, Suehiro Y, Choi I, Yoshimitsu M, Saburi Y, Nosaka K, Utsunomiya A, Kobayashi Y, Yamamoto K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Imada K, Kato K, Moriuchi Y, Yoshimura K, Takahashi T, Tobinai K, Ueda R.

Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.

Br J Haematol. 2019 Feb;184(3):479-483. doi: 10.1111/bjh.15123. Epub 2018 Feb 7. PMID: 29411857.

https://pubmed.ncbi.nlm.nih.gov/29411857/

Inoue Y, Endo S, Matsuno N, Kikukawa Y, Shichijo T, Koga K, Takaki A, Iwanaga K, Nishimura N, Fuji S, Fukuda T, Nosaka K, Matsuoka M.

Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.

Bone Marrow Transplant. 2019 Feb;54(2):338-342. doi: 10.1038/s41409-018-0291-5. Epub 2018 Aug 16. PMID: 30116017.

https://pubmed.ncbi.nlm.nih.gov/30116017/

Maeda M, Muraki Y, Kosaka T, Yamada T, Aoki Y, Kaku M, Kawaguchi T, Seki M, Tanabe Y, Fujita N, Morita K, Yanagihara K, Yoshida K, Niki Y.

The first nationwide survey of antimicrobial stewardship programs conducted by the Japanese Society of Chemotherapy.

J Infect Chemother. 2019 Feb;25(2):83-88. doi: 10.1016/j.jiac.2018.11.001. Epub 2018 Nov 22. PMID: 30473181.

https://pubmed.ncbi.nlm.nih.gov/30473181/

Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Choi I, Otsuka E, Henzan H, Kato K, Nakachi S, Yamamoto H, Fukuda T.

Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma.

Bone Marrow Transplant. 2019 Jan;54(1):134-137. doi: 10.1038/s41409-018-0248-8. Epub 2018 Jun 13. PMID: 29899570.

https://pubmed.ncbi.nlm.nih.gov/29899570/

Nishimura N, Endo S, Kawano Y,

Myeloma Mouse Models in Studying Myeloma Associated Bone Disease.

Reference Module in Biomedical Sciences. 2019 (in press)

https://www.sciencedirect.com/science/article/pii/B9780128012383112486?via%3Dihub

Oda S, Nakaura T, Utsunomiya D, Hirakawa K, Takashio S, Izumiya Y, Tsujita K, Kawano Y, Okuno Y, Hata H, Matsuoka M, Yamashita T, Ueda M, Ando Y, Yamashita Y.

Clinical potential of dual-energy cardiac CT in cardiac amyloidosis.

Alam MM, Kuwata T, Tanaka K, Alam M, Takahama S, Shimura K, Matsuoka M, Fukuda N, Morioka H, Tamamura H, and Matsushita S.

Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors.

Biochem Biophys Rep 20:100687,

https://pubmed.ncbi.nlm.nih.gov/31650039/

Bangham CRM, Miura M, Kulkarni A, and Matsuoka M.

Regulation of Latency in the Human T Cell Leukemia Virus, HTLV-1.

Annu Rev Virol 6:365-385, 2019.

https://pubmed.ncbi.nlm.nih.gov/31283437/

Endo S, Nishimura N, Kawano Y, Ueno N, Ueno S, Tatetsu H, Komohara Y, Takeya M, Hata H, Mitsuya H, Masao M, Okuno Y.

MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells.

Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):246-252. doi: 10.1016/j.bbrc.2018.11.016. Epub 2018 Nov 10. PMID: 30420285.

https://pubmed.ncbi.nlm.nih.gov/30420285/

Saburi M, Ogata M, Itani K, Kohno K, Soga Y, Kondo Y, Kawano Y, Nakayama T.

Rare concurrent indolent B-cell lymphoma and plasmablastic transformation of myeloma.

J Clin Exp Hematop. 2018 Dec 13;58(4):175-179. doi: 10.3960/jslrt.18019. Epub 2018 Oct 10. PMID: 30305474; PMCID: PMC6407474.

https://pubmed.ncbi.nlm.nih.gov/30305474/

Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K.

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

Hematol Oncol. 2018 Dec;36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19. PMID: 30176173.

https://pubmed.ncbi.nlm.nih.gov/30176173/

Yuki A, Shinkuma S, Hayashi R, Fujikawa H, Kato T, Homma E, Hamade Y, Onodera O, Matsuoka M, Shimizu H, Iwata H, Abe R.

CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases.

J Am Acad Dermatol. 2018 Dec;79(6):1039-1046. doi: 10.1016/j.jaad.2018.06.025. Epub 2018 Jun 19. PMID: 29928911.

https://pubmed.ncbi.nlm.nih.gov/29928911/

Hosokawa K, Sugimori C, Ishiyama K, Takamatsu H, Noji H, Shichishima T, Obara N, Chiba S, Ninomiya H, Shirasugi Y, Nakamura Y, Ando K, Ueda Y, Yonemura Y, Kawaguchi T, Nishimura JI, Kanakura Y, Nakao S.

Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure.

Ann Hematol. 2018 Dec;97(12):2289-2297. doi: 10.1007/s00277-018-3443-1. Epub 2018 Jul 24. PMID: 30039297.

https://pubmed.ncbi.nlm.nih.gov/30039297/

Song Z, Wu W, Chen M, Cheng W, Yu J, Fang J, Xu L, Yasunaga JI, Matsuoka M, Zhao T.

Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2.

J Virol. 2018 Nov 27;92(24):e00909-18. doi: 10.1128/JVI.00909-18. PMID: 30258009; PMCID: PMC6258931.

https://pubmed.ncbi.nlm.nih.gov/30258009/

Yasuma-Mitobe K, Matsuoka M.

The Roles of Coinhibitory Receptors in Pathogenesis of Human Retroviral Infections.

Front Immunol. 2018 Nov 27;9:2755. doi: 10.3389/fimmu.2018.02755. PMID: 30538707; PMCID: PMC6277675.

https://pubmed.ncbi.nlm.nih.gov/30538707/

Kumamoto H, Imoto S, Amano M, Kuwata-Higashi N, Baba M, Mitsuya H, Odanaka Y, Shimbara Matsubayashi S, Tanaka H, Haraguchi K.

Synthesis, Anti-HBV, and Anti-HIV Activities of 3′-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines.

ACS Med Chem Lett. 2018 Nov 9;9(12):1211-1216. doi: 10.1021/acsmedchemlett.8b00374. PMID: 30613328; PMCID: PMC6295849.

https://pubmed.ncbi.nlm.nih.gov/30613328/

Naito T, Yasunaga JI, Mitobe Y, Shirai K, Sejima H, Ushirogawa H, Tanaka Y, Nakamura T, Hanada K, Fujii M, Matsuoka M, Saito M.

Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP.

Retrovirology. 2018 Nov 6;15(1):72. doi: 10.1186/s12977-018-0454-x. PMID: 30400920; PMCID: PMC6219256.

https://pubmed.ncbi.nlm.nih.gov/30400920/

Naito T, Yasunaga JI, Mitobe Y, Shirai K, Sejima H, Ushirogawa H, Tanaka Y, Nakamura T, Hanada K, Fujii M, Matsuoka M, Saito M.

Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP.

Retrovirology. 2018 Nov 6;15(1):72. doi: 10.1186/s12977-018-0454-x. PMID: 30400920; PMCID: PMC6219256.

https://pubmed.ncbi.nlm.nih.gov/30400920/

Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.

Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.

Ann Hematol. 2018 Nov;97(11):2081-2088. doi: 10.1007/s00277-018-3412-8. Epub 2018 Jun 26. PMID: 29946911.

https://pubmed.ncbi.nlm.nih.gov/29946911/

Hashi K, Imai C, Yahara K, Tahmina K, Hayashi T, Azuma T, Miyabe-Nishiwaki T, Sato H, Matsuoka M, Niimi S, Okamoto M, Hatakeyama M.

Evaluating the origin and virulence of a Helicobacter pylori cagA-positive strain isolated from a non-human primate.

Sci Rep. 2018 Oct 29;8(1):15981. doi: 10.1038/s41598-018-34425-4. PMID: 30374120; PMCID: PMC6206097.

https://pubmed.ncbi.nlm.nih.gov/30374120/